The objective of the Total TMS Education Conference is to provide an intensive workshop experience that enhances understanding of the clinical operation of the NeuroStar TMS Therapy® System and provides practical strategies for integrating TMS as a standard of care in clinical practice.

This workshop will cover three key elements essential to establishing a successful TMS practice:

  • Reviewing the evidence demonstrating that NeuroStar TMS Therapy is an effective and safe Standard of Care for the treatment of patients with major depression.
  • Outlining a plan to reach the appropriate patients within your practice who may benefit from TMS and setting aside time for the TMS Clinical Consultation with the patient and their loved ones.
  • Discussing a simple plan for implementing overall Best Practices of a successful TMS practice.

The educational weekend was great. Very thorough! The speakers have been very approachable and the training session was informative and hands-on.

- Kelly Cowan, MD; San Antonio, TX (previous attendee)

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

Efficacy for NeuroStar TMS Therapy was established in a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy system to an inactive device. Patients treated with active NeuroStar TMS Therapy received an average reduction in their depression symptom score of 22.1% compared to a 9% average reduction in patients receiving inactive treatment (1).

NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Its effectiveness has also not been established in patients who have failed to receive benefit from two or more prior antidepressant medication at minimal effective dose and duration in the current episode.

The most common adverse event related to TMS is pain or discomfort at or near the treatment area during active TMS (2). There is a rare risk of seizure associated with TMS treatment (0.1% per acute treatment course).

NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit www.NeuroStar.com or call Neuronetics Customer Service at 1-877-600-7555.

1) Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38.
2) Janicak P, et al. Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure and During Reintroduction Treatment. Journal of Clinical Psychiatry, February 2008.